Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911143 | 0.78 | PIM1 (0.43) | ATRALOX5APFEN1PIM1 | |
| SCHEMBL20839015 | 0.78 | PIM1 (0.43) | ATRALOX5APFEN1PIM1 | |
| SCHEMBL23732500 | 0.77 | ATR (0.50) | ATRALOX5APFEN1 | |
| SCHEMBL2681285 | 0.77 | SMN1; SMN2 (0.51) | ATRALOX5APFEN1KDRPRKDC | |
| SCHEMBL20848359 | 0.74 | ATR (0.43) | ATRALOX5APFEN1PIK3CGPIK3CD | |
| SCHEMBL19406768 | 0.73 | ATM (0.34) | ATRPIM1ADK | |
| SCHEMBL15308521 | 0.73 | LRRK2 (0.47) | PIM1PIK3CGPIK3CDKDRPIK3CA | |
| SCHEMBL20848407 | 0.72 | ATR (0.53) | ATR | |
| SCHEMBL15308525 | 0.72 | CSF1R (0.51) | KDRMAPK1 | |
| SCHEMBL23732523 | 0.72 | RAB9A (0.48) | ATRALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684184-B1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20220144801-A1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11229205-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-20200267984-A1 | Herbicidally Active Pyridyl-/Pyrimidyl-Pyrazine Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| WO-2019057723-A1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200267984-A1 | Herbicidally Active Pyridyl-/Pyrimidyl-Pyrazine Derivatives | DDT, HPD, PLPBP | ATR 2054/4885ALOX5AP 506/4885FEN1 1741/4885 |
| US-20220144801-A1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES | DDT, HPD, PLPBP | ATR 2054/4885ALOX5AP 506/4885FEN1 1741/4885 |
| US-11229205-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrazine derivatives | DDT, HPD, PLPBP | ATR 2054/4885ALOX5AP 506/4885FEN1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.